Literature DB >> 29091604

The role of bone marrow morphology in the diagnosis of relapsed acute myeloid leukemia.

B Said1, S Gilles2, D Weisdorf1, A Rashidi1.   

Abstract

Entities:  

Mesh:

Year:  2017        PMID: 29091604     DOI: 10.1038/leu.2017.308

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  9 in total

1.  Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse.

Authors:  K Tobal; J Newton; M Macheta; J Chang; G Morgenstern; P A Evans; G Morgan; G S Lucas; J A Liu Yin
Journal:  Blood       Date:  2000-02-01       Impact factor: 22.113

2.  Is there a need for morphologic exam to detect relapse in AML if multi-parameter flow cytometry is employed?

Authors:  Y Zhou; B L Wood; R B Walter; P S Becker; M-E Percival; M Bar; C Shaw; K Gardner; P Hendrie; J Abkowitz; F R Appelbaum; E Estey
Journal:  Leukemia       Date:  2017-08-18       Impact factor: 11.528

Review 3.  Measurable residual disease testing in acute myeloid leukaemia.

Authors:  C S Hourigan; R P Gale; N J Gormley; G J Ossenkoppele; R B Walter
Journal:  Leukemia       Date:  2017-04-07       Impact factor: 11.528

Review 4.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

5.  Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.

Authors:  David Grimwade; Jelena V Jovanovic; Robert K Hills; Elizabeth A Nugent; Yashma Patel; Rajinder Flora; Daniela Diverio; Katy Jones; Hannah Aslett; Elaine Batson; Kristian Rennie; Roger Angell; Richard E Clark; Ellen Solomon; Francesco Lo-Coco; Keith Wheatley; Alan K Burnett
Journal:  J Clin Oncol       Date:  2009-06-08       Impact factor: 44.544

6.  Assessment of Minimal Residual Disease in Standard-Risk AML.

Authors:  Adam Ivey; Robert K Hills; Michael A Simpson; Jelena V Jovanovic; Amanda Gilkes; Angela Grech; Yashma Patel; Neesa Bhudia; Hassan Farah; Joanne Mason; Kerry Wall; Susanna Akiki; Michael Griffiths; Ellen Solomon; Frank McCaughan; David C Linch; Rosemary E Gale; Paresh Vyas; Sylvie D Freeman; Nigel Russell; Alan K Burnett; David Grimwade
Journal:  N Engl J Med       Date:  2016-01-20       Impact factor: 91.245

Review 7.  Preleukemia: one name, many meanings.

Authors:  H P Koeffler; G Leong
Journal:  Leukemia       Date:  2016-11-30       Impact factor: 11.528

8.  Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy.

Authors:  G L Uy; E J Duncavage; G S Chang; M A Jacoby; C A Miller; J Shao; S Heath; K Elliott; T Reineck; R S Fulton; C C Fronick; M O'Laughlin; L Ganel; C N Abboud; A F Cashen; J F DiPersio; R K Wilson; D C Link; J S Welch; T J Ley; T A Graubert; P Westervelt; M J Walter
Journal:  Leukemia       Date:  2016-10-14       Impact factor: 11.528

9.  Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults.

Authors:  Andrew L Young; Grant A Challen; Brenda M Birmann; Todd E Druley
Journal:  Nat Commun       Date:  2016-08-22       Impact factor: 14.919

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.